Cargando…

Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review

The 22q11.2 deletion syndrome (22q11.2DS) is a multisystem condition and the most prevalent microdeletion syndrome in humans. Approximately 25% of individuals with 22q11.2DS receive antipsychotic treatment. To assess whether patients with 22q11.2DS are vulnerable to adverse effects of antipsychotic...

Descripción completa

Detalles Bibliográficos
Autores principales: de Boer, Janna, Boot, Erik, van Gils, Lissa, van Amelsvoort, Therese, Zinkstok, Janneke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851664/
https://www.ncbi.nlm.nih.gov/pubmed/31407842
http://dx.doi.org/10.1002/ajmg.a.61324
_version_ 1783469662268293120
author de Boer, Janna
Boot, Erik
van Gils, Lissa
van Amelsvoort, Therese
Zinkstok, Janneke
author_facet de Boer, Janna
Boot, Erik
van Gils, Lissa
van Amelsvoort, Therese
Zinkstok, Janneke
author_sort de Boer, Janna
collection PubMed
description The 22q11.2 deletion syndrome (22q11.2DS) is a multisystem condition and the most prevalent microdeletion syndrome in humans. Approximately 25% of individuals with 22q11.2DS receive antipsychotic treatment. To assess whether patients with 22q11.2DS are vulnerable to adverse effects of antipsychotic medication, we carried out a literature review. A systematic search strategy was performed using PubMed (Medline), Embase, PsychInfo, and Cochrane Database of Systematic Reviews. Publications describing adverse effects of antipsychotic medication in patients with 22q11.2DS were included in the review and assessed for their methodological quality. A total of 11 publications reporting on eight trials, cross‐sectional or cohort studies, and 30 case reports were included. The most commonly reported adverse effects can be classified into the following categories: movement disorders, weight gain, seizures, cardiac side effects, and cytopenias. Many of these symptoms are manifestations of 22q11.2DS, also in the absence of antipsychotic medication. Based on the reviewed literature, a causal relation between antipsychotic medication and the reported adverse effects could not be established in the majority of cases. Randomized clinical trials are needed to make firm conclusions regarding risk of adverse effects of antipsychotics in patients with 22q11.2DS.
format Online
Article
Text
id pubmed-6851664
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-68516642019-11-18 Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review de Boer, Janna Boot, Erik van Gils, Lissa van Amelsvoort, Therese Zinkstok, Janneke Am J Med Genet A Research Review The 22q11.2 deletion syndrome (22q11.2DS) is a multisystem condition and the most prevalent microdeletion syndrome in humans. Approximately 25% of individuals with 22q11.2DS receive antipsychotic treatment. To assess whether patients with 22q11.2DS are vulnerable to adverse effects of antipsychotic medication, we carried out a literature review. A systematic search strategy was performed using PubMed (Medline), Embase, PsychInfo, and Cochrane Database of Systematic Reviews. Publications describing adverse effects of antipsychotic medication in patients with 22q11.2DS were included in the review and assessed for their methodological quality. A total of 11 publications reporting on eight trials, cross‐sectional or cohort studies, and 30 case reports were included. The most commonly reported adverse effects can be classified into the following categories: movement disorders, weight gain, seizures, cardiac side effects, and cytopenias. Many of these symptoms are manifestations of 22q11.2DS, also in the absence of antipsychotic medication. Based on the reviewed literature, a causal relation between antipsychotic medication and the reported adverse effects could not be established in the majority of cases. Randomized clinical trials are needed to make firm conclusions regarding risk of adverse effects of antipsychotics in patients with 22q11.2DS. John Wiley & Sons, Inc. 2019-08-13 2019-11 /pmc/articles/PMC6851664/ /pubmed/31407842 http://dx.doi.org/10.1002/ajmg.a.61324 Text en © 2019 The Authors. American Journal of Medical Genetics Part A published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Review
de Boer, Janna
Boot, Erik
van Gils, Lissa
van Amelsvoort, Therese
Zinkstok, Janneke
Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review
title Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review
title_full Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review
title_fullStr Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review
title_full_unstemmed Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review
title_short Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review
title_sort adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: a systematic review
topic Research Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851664/
https://www.ncbi.nlm.nih.gov/pubmed/31407842
http://dx.doi.org/10.1002/ajmg.a.61324
work_keys_str_mv AT deboerjanna adverseeffectsofantipsychoticmedicationinpatientswith22q112deletionsyndromeasystematicreview
AT booterik adverseeffectsofantipsychoticmedicationinpatientswith22q112deletionsyndromeasystematicreview
AT vangilslissa adverseeffectsofantipsychoticmedicationinpatientswith22q112deletionsyndromeasystematicreview
AT vanamelsvoorttherese adverseeffectsofantipsychoticmedicationinpatientswith22q112deletionsyndromeasystematicreview
AT zinkstokjanneke adverseeffectsofantipsychoticmedicationinpatientswith22q112deletionsyndromeasystematicreview